Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 3/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.38 |
| ▸ | SI | P14410 | 3/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5695828 | 0.81 | TGFBR1 (0.42) | RAB9ASMN1; SMN2NPC1GAAHPGD | |
| SCHEMBL4065931 | 0.78 | HCAR3 (0.44) | HCAR3NSD2RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6177854 | 0.76 | NPC1 (0.57) | RAB9ASMN1; SMN2NPC1GAAHPGD | |
| SCHEMBL27627479 | 0.76 | CYP19A1 (0.38) | HCAR3NSD2HPGDNOTUMKDM4E | |
| SCHEMBL6179968 | 0.75 | MAPT (0.46) | RAB9ASMN1; SMN2NPC1GAAHPGD | |
| SCHEMBL27608277 | 0.75 | SLC9A1 (0.41) | NSD2RAB9ASMN1; SMN2NPC1NOTUM | |
| SCHEMBL27627481 | 0.73 | CYP19A1 (0.37) | HCAR3NSD2NOTUMSLC9A1KEAP1 | |
| SCHEMBL4866118 | 0.72 | P2RX7 (0.40) | RAB9ANPC1NPSR1 | |
| SCHEMBL12349868 | 0.72 | HCAR3 (0.57) | HCAR3NSD2RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL1256199 | 0.72 | HCAR3 (0.76) | HCAR3RAB9ASMN1; SMN2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635702-B2 | Imidazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-1542990-B1 | NOVEL IMIDAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PROD INC (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20070088037-A1 | NOVEL IMIDAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER INC. (US) | 2007-04-19 | — | — | US | disclosed |
| US-7153872-B2 | Imidazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060247233-A1 | Thiazoles inhibitors of the alk-5 receptor | SMITHKLINE BEECHAM CORPORATION | 2006-11-02 | — | — | US | disclosed |
| EP-1660494-A2 | THIAZOLES AS INHIBITORS OF THE ALK-5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1542990-A1 | NOVEL IMIDAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004111046-A2 | THIAZOLES AS INHIBITORS OF THE ALK- 5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040106608-A1 | Novel imidazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| WO-2004026859-A1 | NOVEL IMIDAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247233-A1 | Thiazoles inhibitors of the alk-5 receptor | SMAD3, ALK, SMAD2 | HCAR3 532/4885NSD2 4558/4885RAB9A 4363/4885 |
| US-20040106608-A1 | Novel imidazole compounds as transforming growth factor (TGF) inhibitors | SMAD3, TGFBR1, TGFBR2 | HCAR3 2875/4885NSD2 3051/4885RAB9A 2674/4885 |
| US-20070088037-A1 | NOVEL IMIDAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | TGFBR1, SMAD3, TGFBR2 | HCAR3 2901/4885NSD2 2883/4885RAB9A 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.